Boostimmune Secures Japanese Patent for TCTP-Targeting Cancer Therapy

Unlike many pharmaceutical patents restricted to specific amino acid sequences, this grant is defined by its mechanism of action. The claims cover antibodies that functionally inhibit extracellular TCTP, specifically targeting the reduction of polymorphonuclear MDSCs. This broad protection strengthens the intellectual property foundation for the company’s lead candidate, BIO101, and provides a framework for future therapeutics using similar pathways.

The research behind this development originated in the laboratory of Tadatsugu Taniguchi, a Professor Emeritus at the University of Tokyo. His team’s 2021 findings in Nature Immunology established that TCTP functions as a signaling molecule that recruits immunosuppressive cells to the tumor microenvironment. Boostimmune, co-founded by Taniguchi and CEO Gwanghee Lee, has since refined this discovery into a clinical-stage program.

Dr. Lee noted that the patent’s functional scope is critical for the company’s commercial strategy in Japan. By securing rights to the underlying mechanism rather than just a specific antibody structure, the firm intends to accelerate the development of BIO101 while exploring strategic partnerships with global pharmaceutical entities. The company continues to focus on this pathway to dismantle the immunosuppressive barriers that prevent effective cancer treatments.